Individuals experiencing depression frequently face ongoing memory issues, challenges with concentration, and persistent mental “brain fog,” even after their mood improves. Recent research indicates that certain prescription medications approved for chronic constipation may effectively alleviate these lingering cognitive symptoms.
The findings are derived from a study in psychiatry led by Dr. Angharad de Kates from the University of Birmingham, in collaboration with the University of Oxford. This research explored the potential of approved laxatives in enhancing cognitive functions such as thinking and memory, which are often impaired in depression and various mental health disorders.
Exploring Laxatives for Cognitive Enhancement in Depression
The focus of the study was on prucalopride, a drug currently sanctioned for treating chronic constipation. It operates by activating a specific serotonin receptor (5-HT4 R), present in both the gut and brain. This research received backing from the National Institute for Health and Care Excellence (NIHR) Biomedical Research Center, Oxford Health.
The clinical trial comprised 50 adults with a history of depression. Participants had previously experienced a depressive episode but had maintained recovery for a minimum of 6 months prior to the study and were not on any medication at that time. They were randomly assigned to receive either 2 mg of prucalopride (the standard approved dosage for chronic constipation) or a placebo for a duration of 7 to 10 days.
Prior to and following the treatment, participants undertook a series of tests aimed at evaluating executive function, as well as short- and long-term memory, alongside emotional processing. Results indicated that the group receiving prucalopride outperformed the placebo group, exhibiting faster and more accurate responses in cognitive tests.
Dr. Angharad de Kates stated, “Cognitive challenges, such as brain fog, are significant yet frequently underestimated aspects of depression that can linger even as mood improves. Our study indicates that targeted serotonin 5-HT4 receptor medications, prevalent in chronic constipation treatments, may also boost cognitive function in individuals with a history of depression.”
“These insights advocate for further inquiry into the potential repurposing of 5-HT4 targeting medications for depression or the development of similar drugs aimed at helping those with depression and other mental health issues.”
Enhancing Memory and Concentration
Participants on prucalopride followed a regimen for 5 to 8 days, reaching the approved 2 mg dose. Researchers reported no significant side effects during the trial.
Dr. Angharad de Kates elaborated, “Prucalopride functions as a mild laxative that stimulates bowel movements; thus, participants did not experience any severe gastrointestinal discomfort.”
Cognitive evaluations included:
- Auditory Verbal Learning and Memory Task Test (AVLT) for declarative memory,
- Working memory tasks (N-back),
- Tests assessing executive function (such as attention and processing speed: TMT, DSST).
The team also implemented three emotional cognition tests designed to gauge emotional reasoning.
When compared with the “cold” cognitive assessments regarding memory and executive function, participants who received prucalopride exhibited enhanced accuracy (z=+0.59) and quicker reactions (z=-0.69) relative to those who received a placebo.
Preliminary Evidence for Innovative Therapeutics
Professor Susannah Murphy, Associate Professor at the University of Oxford and lead author of the study, expressed, “For many, the journey to recovery from depression remains unfinished as cognitive functions such as memory and concentration continue to suffer. This research offers early evidence that 5-HT4 receptor agonists may contribute to restoring cognitive functions, paving the way for exciting new treatment possibilities.”
The research team aims to further explore treatments addressing cognitive challenges linked to major depressive disorder. Memory decline, attentional deficits, and concentration issues are prevalent among those with depression and can persist long after other symptoms have subsided. Previous studies have hinted that 5-HT4 receptor agonists may lower the risk of depression, suggesting this class of drugs could provide multiple mental health advantages.
Source: www.sciencedaily.com